Get started

Pennystocks

$DTSS is gonna fall todayPupm&Dump trading strategy idea. $DTSS is rising too much despite the news today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $3,50; stop-loss — $4,00; take-profit — $2,50; Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:DTSSShort
by KozakHlib
$CNET is gonna fall todayPupm&Dump trading strategy idea. $CNET is rising too much despite the news today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $2,97; stop-loss — $3,30; take-profit — $2,31; Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:CNETShort
by KozakHlib
$OGEN is gonna fall todayPupm&Dump trading strategy idea. $OGEN is rising too much despite the news today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $0,89; stop-loss — $0,95; take-profit — $0,77; Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
AMEX:OGENShort
by KozakHlib
$PTE is gonna fall todayPupm&Dump trading strategy idea. $PTE is rising too much without specific news today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $1,54; stop-loss — $1,64; take-profit — $1,34; Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
PShort
by KozakHlib
3
This ACRX Penny Stock Could Surge Over 300%, Say AnalystsThis ACRX Penny Stock Could Surge Over 300%, Say Analysts AcelRx is a pharmaceutical company dedicated to the creation of safer treatments for acute pain, developing synthetic opioid drugs for sublingual (under the tongue) dosing. The company’s main product, Sufentanil, was approved by the FDA under the name Dsuvia in 2018, and by the EU as Dzuveo that same year. A second sublingual Sufentanil system, under the name Zalviso, has also been approved for use by the EU, and is in Phase 3 trial in the US. In its most recent earning report, the company showed $1.4 million at the top line, driven by $1.3 million in product sales. The sales figure was up 433% sequentially, and the total revenue figure was up 133% year-over-year. Cantor analyst Brandon Folkes is upbeat on Dsuvia’s prospects as an alternative to current opioid treatments, and he believes that potential will boost the company’s stock. As ACRX launches a true alternative to IV opioids, we expect investors to begin to appreciate the value of the product. In line with his bullish stance, Folkes rates ACRX a Buy, and his $9 price target implies room for a stunning 552% upside potential in the next 12 months. finance.yahoo.com
A
by AlenCiken
30% Gain on $GSATI wish I would have remembered to post this before the move happened, but I forgot. So I will just show my entry and exit points and why I had them. I set my entry point based on the trend low of the previous uptrend. This is what caused me to catch an absolute perfect falling knife for entry. Price then steadily rose to try and test the trend high of the previous downtrend. The trend high level ended getting broken by a 12% move up. The move had high volume so I continued to hold. I ended up selling when the volume started decreasing.
GLong
by A_x_A
$LJPC is gonna fall todayPupm&Dump trading strategy idea. $LJPC is rising too much despite the news today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $6,20; stop-loss — $6,70; take-profit — $5,20; Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
LShort
by KozakHlib
1
MMED still looks like a buy before NASDAQ uplistingHello fellow bulls and future Warren Buffetts, hope you all had a good Christmas because the gift you received from MMED was a 92 Million dollars public deal, this is an extremely good news because now MMED can operate for years without worrying about debt nor the cost of operating a pharma company. This is a sign that this company can grow long term and perhaps become something big. Now, the CEO of MMED said in the interview that closing the public deal will let them work full time on the NASDAQ up-listing goal. As we can see from their perspectives, getting up-listed on NASDAQ is not an easy job. It requires a lot of time and money, which now the company got both of these resources for sure. I said last time that up-listing may be between December-January. However, the 92 millions dollars public deal announcement came out of no where and delayed the plans and decreased the stock price. My opinion, the final train is loading up before the departure and you still have time to hop in. I bought more shares when it dropped to 3.6$/share. People sell because they look for fast money, you need to give MMED some time, it already went 400% in one month. I am going to hold and speculate that between January and February, we will have some update about the NASDAQ up-listing news, we will even have a chance to grow within this time period. To the moon bois, MMED will reach 10$ when up-listing will be announced. And on the day of up-listing, people will sell their expensive CMPS shares and buy more MMED, driving it to 20$. Good luck mates!
MLong
by DumpItAgain
3
NUMI can possibly take the same path as MMEDHello fellow bulls and bag holders, December was a crazy volatile month for psychedelics penny stocks, and some of u maybe lost or won, me? I just bag hold like Warren Buffet or something. I will upload an update on MMED soon but I wanted to tell you guys that NUMI is a cheap and has the same potentials as MMED to rise. It only needs a small push from MMED with their NASDAQ up-listing announcement. There are 3 points where it can spike from because theses are the points where I predict the news about MMED up-listing will come out. If you don't understand them, then I will just say it more simple. Just bag hold NUMI, TRIP or MMED for 2 months and one of this points have a chance to spike, possibly profiting on 400% within 2 months just like MMED did. However, NUMI may be cheaper than MMED, it is certainly does not have a lot of cash to operate long term like MMED. Without the trend or public offerings, this company will get into big amounts of debts and die eventually, so ride it only for the trend and not for what they promise. Good Luck mates and to the moon!!!!!!!!!!!!!!!!!!
NLong
by DumpItAgain
$SNDL is gonna fall todayPupm&Dump trading strategy idea. $SNDL is rising without enough specific strong news today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $0,65; stop-loss — $0,74; take-profit — $0,56; Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:SNDLShort
by KozakHlib
10